Core business strength offsets decline in Covid-related product sales
- Labcorp reports higher fourth-quarter revenue
- Core business strength offsets decline in Covid-related product sales
- Adjusted earnings exceed analyst expectations
- Sales rise over 3% to $3.03 billion
- Quarterly organic sales increase by 1.5%
- Labcorp targets adjusted earnings of $14.30 to $15.40 a share for 2024
- Enterprise-wide revenue growth expected to be 4.7% to 6.5% in 2024
Labcorp, the diagnostics and drug-development company, reported higher fourth-quarter revenue driven by the strength of its core business, which offset the decline in sales of Covid-related products. The company swung to a fourth-quarter loss of $167.1 million, or $1.95 a share, compared to a profit of $76.1 million, or 86 cents a share, in the same period last year. However, adjusted earnings, excluding one-time items, were $3.30 a share, surpassing analyst expectations of $3.26 a share. Sales rose by more than 3% to $3.03 billion, exceeding the $3.02 billion expected by analysts. Quarterly organic sales increased by 1.5%. Labcorp is targeting adjusted earnings of $14.30 to $15.40 a share for 2024, slightly below analysts’ expectations of $14.60 a share. The company also expects enterprise-wide revenue growth of 4.7% to 6.5% in 2024.
Public Companies: Laboratory Corporation of America (Labcorp)
Private Companies:
Key People:
Factuality Level: 8
Justification: The article provides specific financial information about Laboratory Corporation of America’s fourth-quarter revenue, earnings, and sales, which can be verified. The information is supported by data from the company and analysts. However, the article does not provide any context or analysis of the company’s performance, which limits its overall factuality level.
Noise Level: 7
Justification: The article provides financial information about Laboratory Corporation of America’s fourth-quarter results, including revenue, earnings, and sales. It also includes analysts’ expectations for future earnings and revenue growth. However, it lacks analysis of long-term trends, antifragility, accountability, scientific rigor, and actionable insights. The article stays on topic and supports its claims with data and examples, but it mainly focuses on financial figures without providing deeper analysis or implications.
Financial Relevance: Yes
Financial Markets Impacted: Labcorp’s financial performance and projections may impact investor sentiment and the stock price of the company.
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article primarily focuses on Labcorp’s financial performance and projections, with no mention of any extreme events or significant disruptions.
www.marketwatch.com 
